ClinicaliQ Trial Snapshot
- Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry — Recruiting • Neurology • NCT02071134.
- What is being tested: Real-world outcomes and effectiveness of Boston Scientific's Vercise DBS System for Parkinson's disease treatment, including the role of Image Guided Programming (IGP) technology in optimizing patient outcomes across diverse clinical settings.
- Patient eligibility overview: The registry enrolls patients with Parkinson's disease who are candidates for or have received the Vercise DBS System, capturing international data across multiple healthcare centres to ensure diverse patient populations and clinical contexts.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility Snapshot
- Key Inclusion Criteria: * Meets criteria established in locally applicable Vercise System Direction for Use * At least 18 years old Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.